Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| NCT ID | NCT05665595 |
| Title | A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010) |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase III |
| Variant Requirements | No |
| Sponsors | Merck Sharp & Dohme LLC |
| Indications | |
| Therapies | |
| Age Groups: | adult | child | senior |
| Covered Countries | USA | NZL | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS |